G1 Therapeutics
GTHX
GTHX was delisted on the 17th of September, 2024.
27 hedge funds and large institutions have $174M invested in G1 Therapeutics in 2017 Q2 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
35.34% more ownership
Funds ownership: 0% → 35.34% (+35%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
+$47M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$14.6M |
| 4 |
Emerald Advisers
Leola,
Pennsylvania
|
+$12.4M |
| 5 |
Boxer Capital Management
San Diego,
California
|
+$11M |
Top Sellers
GTHX Hedge Fund Activity: Q2 2017 in Review
27 of the 4,025 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics (GTHX) for Q2 2017, worth a combined $174M.
Buyers outnumbered sellers: 27 funds opened new GTHX positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $47M.
- 27 institutional investors held G1 Therapeutics (GTHX) as of Q2 2017, up from 0 in Q1 2017.
- Funds reported $174M of G1 Therapeutics stock for Q2 2017.
- 27 funds opened new G1 Therapeutics positions in Q2 2017 and 0 closed out, a net change of +27 holders.
- The largest G1 Therapeutics buyer in Q2 2017 was RA Capital Management, an estimated $47M added.
Based on aggregated 13F filings for Q2 2017.